Treatment Details – 12.7 months

Survival: 12.7 months
Toxicity Grade:4
Treatments: Chemotherapy
Drugs: Gemzar
Hospital:C. Forlanini Hospital
Date: 1/2005

Patients: This Phase II study involved 28 patients with mesothelioma, of whom 26 were evaluated. Twenty-two patients were men, and six were women. The median age was 63 years. Twenty-two patients had stage 3 or 4 disease. None of the patients had received prior treatment.

Treatment: The treatment consisted of two chemotherapeutic agents: epirubicin and gemcitabine. In addition, the six patients who responded to chemotherapy were also administered interleukin.

Toxicities: Grade 3-4 toxicities included: leukocytopenia, nausea, and vomiting.

Results: In 26 evaluable patients, the median survival was 12.7 months.

Correspondence: Dr Luigi Portalone, MD

Get your free copy of
“Surviving Mesothelioma” Today!